Concert Pharma (CNCE) Tops Q3 EPS by 11c

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.72), $0.11 better than the analyst estimate of ($0.83).

“Over the past several months, we have presented important clinical advances for both of our proprietary candidates – CTP-543 for alopecia areata and CTP-692 for schizophrenia – which support their continued development, and have been broadly shared with the clinical community,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We believe that our CTP-543 Phase 2 data set a new bar for clinical efficacy in the treatment of alopecia areata. Additionally, we are pleased that CTP-692 demonstrated favorable clinical properties including an excellent safety profile in its Phase 1 studies, and we look forward to advancing it into its first efficacy trial later this year.”

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c